期刊文献+

Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro 被引量:4

Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro
下载PDF
导出
摘要 For more than 70 years, it has been believed that a severe reduction of serum androgen levels caused regression of prostate cancer (PCa) and that increasing androgen levels enhanced growth of PCa. However, numerous recent studies have questioned this traditional belief. In our study, LNCaP and MDA PCa 2b PCa cells were treated with various levels of androgens for 10 or 20 days, and the cell growth was measured with crystal violet mitogenic assay. The results indicated that the effect of androgens on the proliferation of PCa cells occurs in a biphasic pattern, with the androgen levels promoting optimal cell growth at approximately 0.23 ng m1-1 for LNCaP cells and between I and 2 ng m1-1 for MDA PCa 2b cells. Both of the optimal androgen levels are within the adult men's physiological low range (〈2.4 ng ml-1). At lower concentrations than the optimal androgen level, increasing androgen concentration promoted the proliferation of PCa cells. However, at the higher concentrations, increasing androgen concentration resulted in a dose-dependent proliferative inhibition. We conclude that physiologically normal levels of androgen inhibit the proliferation of PCa cells in vitro. However, at very low levels androgens are essential for initial growth of PCa cells. For more than 70 years, it has been believed that a severe reduction of serum androgen levels caused regression of prostate cancer (PCa) and that increasing androgen levels enhanced growth of PCa. However, numerous recent studies have questioned this traditional belief. In our study, LNCaP and MDA PCa 2b PCa cells were treated with various levels of androgens for 10 or 20 days, and the cell growth was measured with crystal violet mitogenic assay. The results indicated that the effect of androgens on the proliferation of PCa cells occurs in a biphasic pattern, with the androgen levels promoting optimal cell growth at approximately 0.23 ng m1-1 for LNCaP cells and between I and 2 ng m1-1 for MDA PCa 2b cells. Both of the optimal androgen levels are within the adult men's physiological low range (〈2.4 ng ml-1). At lower concentrations than the optimal androgen level, increasing androgen concentration promoted the proliferation of PCa cells. However, at the higher concentrations, increasing androgen concentration resulted in a dose-dependent proliferative inhibition. We conclude that physiologically normal levels of androgen inhibit the proliferation of PCa cells in vitro. However, at very low levels androgens are essential for initial growth of PCa cells.
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2014年第6期864-868,共5页 亚洲男性学杂志(英文版)
关键词 ANDROGEN PROLIFERATION prostate cancer TESTOSTERONE androgen proliferation prostate cancer testosterone
  • 相关文献

参考文献23

  • 1Huggins C, Hodges CV. Studies on prostatic cancer.The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
  • 2Khera M, Grober ED, Najari B, Colen JS, Mohamed O, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009; 6: 1165-70.
  • 3Morgentaler A. Testosterone therapy for men at risk for or with history of prostate cancer. Curr Treat Options Onco12006; 7: 363-9.
  • 4Rhoden EL, Averbeck MA, Testosterone therapy and prostate carcinoma. Curr Urol Rep 2009; 10: 453-9.
  • 5Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-71.
  • 6Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, et al. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci 2011; 18: 63.
  • 7van Oort IM, Kok DE, Kiemeney LA, Hulsbergen-van de Kaa CA, Witjes JA. A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or "insignificant". Urol Onco12009; 27; 509-13.
  • 8Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Uro12000; 163: 824-7.
  • 9Lane BR, Stephenson A J, Magi-Galluzzi C, Lakin MM, Klein EA. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology 2008; 72: 1240-5.
  • 10Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, etal. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173-81.

同被引文献4

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部